@article{b4a1a70a8f004b7cbc96136d673a1144,
title = "Favorable Response to Pembrolizumab in a Patient With Metastatic Castration-Resistant Prostate Cancer Progressing While Receiving Enzalutamide",
keywords = "CDK12, Checkpoint inhibitor, Homologous recombination, Mismatch-repair deficiency, PDL-1",
author = "Dib, {Elie G.} and Antonarakis, {Emmanuel S.} and Wasco, {Matthew J.} and Powell, {Steven F.}",
note = "Funding Information: E.S.A. is a paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, ESSA, AstraZeneca, Clovis, and Merck; he has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Bristol-Myers Squibb, AstraZeneca, Clovis, and Merck; and he is the coinventor of a biomarker technology that has been licensed to Qiagen. S.F.P. received research support to his institution from Merck, Bristol-Myers Squibb, Pfizer, Vyriad, Genentech, and Novartis; and he has served as a consultant for Bristol-Myers Squibb. The other authors have stated that they have no conflict of interest.",
year = "2019",
month = apr,
doi = "10.1016/j.clgc.2018.11.021",
language = "English (US)",
volume = "17",
pages = "e365--e368",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "2",
}